Table 1. Correlation of miR-145 expression profile with PCa patients' Gleason score, Clinical stage, PSA, DRE and age.
| |
|
No. of patients (%) |
|
|
|---|---|---|---|---|
| Variable | No. of patients | miR-145-negativea | miR-145-positivea | P-value |
|
Gleason score | ||||
| 5 | 2 | 0 (0.0) | 2 (100.0) | 0.015b |
| 6 | 22 | 5 (22.7) | 17 (77.3) | |
| 7 (3+4) | 25 | 10 (40.0) | 15 (60.0) | |
| 7 (4+3) | 14 | 9 (64.3) | 5 (35.7) | |
| 8 | 7 | 5 (71.4) | 2 (28.6) | |
| 9 |
3 |
3 (100.0) |
0 (0.0) |
|
|
Gleason score | ||||
| ⩽6 | 24 | 5 (20.8) | 19 (79.2) | 0.004b |
| 7 | 39 | 19 (48.7) | 20 (51.3) | |
| ⩾8 |
10 |
8 (80.0) |
2 (20.0) |
|
|
Clinical stage | ||||
| pT2a | 17 | 4 (23.5) | 13 (76.5) | 0.047b |
| pT2b | 18 | 6 (33.3) | 12 (66.7) | |
| pT2c | 10 | 5 (50.0) | 5 (50.0) | |
| pT3a | 15 | 7 (46.7) | 8 (53.3) | |
| pT3b |
13 |
10 (76.9) |
3 (23.1) |
|
|
Clinical stage | ||||
| ⩽ pT2c | 45 | 15 (33.3) | 30 (66.7) | 0.030c |
| ⩾ pT3a |
28 |
17 (60.7) |
11 (39.3) |
|
|
PSA (ng ml–1) | ||||
| <4.0 | 7 | 0 (0.0) | 7 (100.0) | <0.001b |
| 4.0–10.0 | 43 | 14 (32.6) | 29 (67.4) | |
| ⩾ 10.0 | 22 | 18 (81.8) | 4 (18.2) | |
| Unknown |
1 |
|
|
|
|
DRE | ||||
| Negative | 27 | 9 (33.3) | 18 (66.7) | 0.145b |
| Positive | 44 | 23 (52.3) | 21 (47.7) | |
| Unknown |
2 |
|
|
|
|
Age (years) | ||||
| <65 | 36 | 15 (41.7) | 21 (58.3) | 0.887b |
| 65–74 | 32 | 15 (46.9) | 17 (53.1) | |
| ⩾75 | 4 | 2 (50.0) | 2 (50.0) | |
| Unknown | 1 | |||
Abbreviations: DRE=digital rectal examination; PCa=prostate cancer; RQ=relative quantification.
a
Cutoff =2.97 × 103 RQ units, equal to the 45th percentile of the PCa patients' cohort.
b
Calculated by χ2 test.
c
Calculated by Fisher's exact test.